


Uscom Achieves First Cash Flow Positive Quarter

Appendix 4C

Record cash receipts - \$1.41M (up 41%) Record cash receipts from customers - \$0.91M (up 43%) Cash flow positive - \$0.22M Cash on hand - \$2.13M

SYDNEY, Australia, Wednesday 19th April 2017: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) has achieved its first ever cash flow positive quarter in another record period for the Company. The results in the attached Appendix 4C – Quarterly cash flow report for the consolidated entity for the period ended 31 March 2017 (the **Quarter**) are in Australian dollars.



Quarterly Customer Receipts

Highlights

For the Quarter, we note the following:

- Record total cash receipts for quarter \$1.41M up 41% on 2016 Q3 (from \$1.00M)
- Record customer cash receipts \$0.91M, up 43% on 2016 Q3 (from \$0.64M)
- Net cash flow +\$0.22M (from -\$0.06M in 2016 Q3)
- Cash on hand \$2.13M (from \$1.00M in 2016 Q3)

The Uscom 4C results for the quarter demonstrate record total cash receipts of \$1.41M, up 41% on the corresponding prior Q3 (\$1.00M), and record customer cash receipts of \$0.91M, up 43% on the prior Q3 (\$0.64M). Cash flow for the period was +\$0.22M, up from the 2016 Q3 of -\$0.06M. Cash on hand at the end of the period was \$2.13M, up from \$1.00M reported in 2016 Q3. An additional \$1.2M in options remains outstanding at an exercise price of 25c and exercisable by 31st July 2017. An R&D tax refund of \$0.50M was received during the current period, while \$0.37M was received in the 2016 Q3.



Uscom CEO Associate Professor Rob Phillips said, "Our first cash flow positive quarter is especially satisfying as it comes on top of four consecutive years of 40%+ CAGR revenue growth. While both revenue and costs will continue to be lumpy, our strategy remains firmly focused on long term sustained revenue growth, profitability and, ultimately, shareholder dividends. During the quarter we have been completing the BP+, BP+ Reporter, SpiroSonic and SpiroReporter devices (seven products in all), and finalising regulatory submissions for approvals for their sale in the main jurisdictions of China, Europe and the USA. Once the devices are approved then a number of one off costs will be replaced by revenue. The devices are now all in regulatory cycles in all regions and we look forward to receiving the revenue growth that will flow once the approvals are received and our new and established distributor channels are activated. It is these supplementary revenue streams which we expect to accelerate our current growth over the coming years. We have invested wisely in acquisitions and new product development, and we are now poised for continuing and accelerated revenue growth."

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The devices and technologies are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD diagnosis and medication monitoring.



About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specializing in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced hemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A: A simple to use, cost-effective and non-invasive advanced hemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Pediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and pediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterization. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand-alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyze pulse pressure waves and generate a summary report.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialized for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary **SpiroReporter**, an innovative stand-alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyze spirometry outputs and generate a summary report.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au Brett Crowley Company Secretary secretary@uscom.com.au

+Rule 4.7B

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity **USCOM LIMITED** Quarter ended ("current quarter") ABN

35 091 028 090

31 March 2017

Con	solidated statement of cash flows	Current quarter \$A	Year to date (9 months) \$A
1.	Cash flows from operating activities		
1.1	Receipts from customers	913,744	2,156,711
1.2	Payments for		
	(a) research and development	(174,940)	(518,570)
	 (b) product manufacturing and operating costs 	(192,298)	(607,565)
	(c) advertising and marketing	(144,474)	(424,408)
	(d) leased assets	(39,485)	(118,734)
	(e) staff costs	(435,340)	(1,077,647)
	(f) administration and corporate costs	(202,809)	(604,137)
1.3	Dividends received (see note 3)		
1.4	Interest received	483	14,967
1.5	Interest and other costs of finance paid		
1.6	Income taxes paid		
1.7	Government grants and tax incentives	496,634	621,617
1.8	Other (provide details if material)		
1.9	Net cash from / (used in) operating activities	221,515	(557,766)

2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(702)	(44,075)
	(b) businesses (see item 10)		(100,000)
	(c) investments		1

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B

Con	solidated statement of cash flows	Current quarter \$A	Year to date (9 months) \$A
	(d) intellectual property	(4,384)	(22,799)
	(e) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment		
	(b) businesses (see item 10)		
	(c) investments		
	(d) intellectual property		
	(e) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(5,086)	(166,874)

3.	Cash flows from financing activities	
3.1	Proceeds from issues of shares	
3.2	Proceeds from issue of convertible notes	
3.3	Proceeds from exercise of share options	29,750
3.4	Transaction costs related to issues of shares, convertible notes or options	(6,368)
3.5	Proceeds from borrowings	
3.6	Repayment of borrowings	
3.7	Transaction costs related to loans and borrowings	
3.8	Dividends paid	
3.9	Other (provide details if material)	
3.10	Net cash from / (used in) financing activities	- 23,382

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	1,922,086	2,840,165
4.2	Net cash from / (used in) operating activities (item 1.9 above)	221,515	(557,766)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(5,086)	(166,874)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	23,382

Con	solidated statement of cash flows	Current quarter \$A	Year to date (9 months) \$A
4.5	Effect of movement in exchange rates on cash held	(5,212)	(5,604)
4.6	Cash and cash equivalents at end of quarter	2,133,303	2,133,303

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A	Previous quarter \$A
5.1	Bank balances	2,091,734	1,880,517
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details) – Term Deposit	41,569	41,569
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,133,303	1,922,086

6.	Payments to directors of the entity and their associates	Current quarter \$A
6.1	Aggregate amount of payments to these parties included in item 1.2	91,432
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
6.3	Include below any explanation necessary to understand the transaction items 6.1 and 6.2	ons included in

7.	Payments to related entities of the entity and their associates	Current quarter \$A
7.1	Aggregate amount of payments to these parties included in item 1.2	
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3	Include below any explanation necessary to understand the transaction items 7.1 and 7.2	ns included in

8.	Financing facilities available Add notes as necessary for an understanding of the position	Total facility amount at quarter end \$A	Amount drawn at quarter end \$A
8.1	Loan facilities		
8.2	Credit standby arrangements		
8.3	Other (please specify)		
8.4	Include below a description of each facil	ity above, including the lender.	interest rate and

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

9.	Estimated cash outflows for next quarter	\$A
9.1	Research and development	160,000
9.2	Product manufacturing and operating costs	200,000
9.3	Advertising and marketing	140,000
9.4	Leased assets	40,000
9.5	Staff costs	450,000
9.6	Administration and corporate costs	250,000
9.7	Other (provide details if material)	
9.8	Total estimated cash outflows	1,240,000

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity		
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

(Director)

Date: 19 April 2017.

Sign here:

Print name: Rob Phillips

Notes

- 1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.